2 active not recruiting, 1 unknown. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 2, Unknown 1 |
| Phase 2 | 3 | Active not recruiting 2, Unknown 1 |
Follow TNO155: new trials by email Literature Review of TNO155 trials Research Report on TNO155
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments Opnurasib, TNO155, trametinib - Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 25 | 2026-06-08 | 2026-10-23 |
| Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation JDQ443, TNO155, tislelizumab - KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 344 | 2021-02-24 | 2026-10-19 |
| Lorlatinib Combinations in Lung Cancer Lorlatinib, Crizotinib, Binimetinib - Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation | Phase 1 / Phase 2 | Unknown | Massachusetts General Hospital | 96 | 2020-05-01 | 2021-03-10 |
Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Lung Neoplasms (2) · Neoplasm Metastasis (1) · Recurrence (1)
Novartis Pharmaceuticals (2) · Massachusetts General Hospital (1)
Belgium (2) · Canada (2) · China (2) · Denmark (2) · France (2) · Italy (2) · Japan (2) · South Korea (2) · Spain (2) · United States (2) · Australia (1) · Germany (1) · Hong Kong (1) · Malaysia (1) · Netherlands (1)
2025 (1)